Linden Hires New Pharma Pro

Linden Capital Partners has hired John Poulos as a new Operating Partner. Mr. Poulos will serve as the lead Operating Partner supporting Linden’s pharmaceutical effort and will be responsible for sourcing and evaluating new platform investments and opportunities to acquire or license products. Mr. Poulos most recently served as Vice President, Head of Business Development and Acquisitions for AbbVie, a 2013 pharmaceutical company spin-off of Abbott Laboratories.

Mr. Poulos’ 38 year career with Abbott and AbbVie included executive roles in finance, general management, licensing, business development, and acquisitions, including time spent serving as General Manager of Abbott’s Middle East, Africa, and Turkey business. For the last twenty years, Mr. Poulos led teams in business development and acquisitions.

“John brings a wealth of experience, a track record of successful transactions, and deep relationships across the global pharmaceutical industry,” said Tony Davis, President and Managing Partner at Linden. “He complements our ongoing efforts in both the branded and generic pharmaceutical space.”

“After spending my career with Abbott and AbbVie, I’m thrilled to partner with a healthcare exclusive firm that values my three decades of operational and transactional experience,” said Mr. Poulos. “Over the last several months, we’ve built a strong relationship, and I look forward to continuing with a formal, proactive effort to acquire products and businesses in the pharmaceutical sector.”

During his career, Mr. Poulos was instrumental in the execution of numerous acquisitions including Abbott’s buy of Knoll/BASF Pharma in 2001 for $6.9 billion, and AbbVie’s buy of Pharmacyclics in 2015 for $21.0 billion. Mr. Poulos currently serves on the board of Faron Pharmaceuticals. He holds a Bachelor of Science and a Master in Business Administration from Indiana University.

Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based upon three elements: healthcare and life science industry specialization; integrated financial and operating expertise; and strategic relationships with large corporations. The firm is based in Chicago (www.lindenllc.com).

© 2017 Private Equity Professional | May 20, 2017